Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

被引：0

作者：

Mauro, Michael ^{[1
]}

Paquette, Ronald ^{[2
]}

Hehlmann, Rudiger ^{[3
]}

Williams, Loretta A. ^{[4
]}

Goldberg, Stuart L. ^{[5
]}

Michallet, Mauricette ^{[6
]}

Gambacorti-Passerini, Carlo ^{[7
]}

Tang, Derek ^{[8
]}

DeGutis, Irene S. ^{[8
]}

McBride, Ali ^{[8
]}

Parsons, Lori ^{[9
]}

Montelongo, Monica Z. ^{[9
]}

Cortes, Jorge E. ^{[10
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[3] Heidelberg Univ, Heidelberg, Germany

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[6] Ctr Lutte Canc Leon Berard, Lyon, France

[7] Univ Milano Bicocca, Milan, Italy

[8] Bristol Myers Squibb, Princeton, NJ USA

[9] ICON plc, Blue Bell, PA USA

[10] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163080

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

632

引用

页码：9624 / 9625

页数：2

共 50 条

[1] Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia
Bostan, Hayri
Toptas, Tayfur
Tanrikulu, Funda Pepedil
Kut, Kevser
Arikan, Fatma
Yilmaz, Fergun
Atagunduz, Isik
Firatli-Tuglular, Tulin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 836 - 842
[2] Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Cortes, Jorge E.
Chen, Clara
Davis, Catherine
Goldberg, Stuart L.
Mauro, Michael J.
BLOOD, 2019, 134
[3] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
Swords R.
Alvarado Y.
Cortes J.
Giles F.J.
Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
[4] Second generation tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia
le Coutre, P.
Baskaynak, G.
Schwarz, M.
Petereit, C.
Westermann, J.
Dorken, B.
ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
[5] Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Trivedi, Digisha
Amin, Shahla
Zhu, Ling
Joo, Sam
Kawabata, Hugh
Darkow, Theodore
Hebden, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors
Maeda, Yasuhiro
Okamoto, Atsushi
Kawaguchi, Shin-ichiro
Konishi, Akiko
Yamamoto, Kenta
Eguchi, Go
Kanai, Yoshitaka
Yamaguchi, Terufumi
ACTA HAEMATOLOGICA, 2017, 138 (03) : 140 - 142
[7] First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
Oehler, Vivian G.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 228 - 236
[8] Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
Shacham Abulafia, Adi
Shemesh, Sivan
Rosenmann, Lena
Berger, Tamar
Leader, Avi
Sharf, Giora
Raanani, Pia
Rozovski, Uri
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
[9] Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
McFarland, K. Leigh
Wetzstein, Gene A.
CANCER CONTROL, 2009, 16 (02) : 132 - 140
[10] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Breccia, M.
Alimena, G.
CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401

← 1 2 3 4 5 →